Antimüllerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization
Antimüllerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization
Objective
To assess the accuracy of antimüllerian hormone (AMH) in predicting cumulative live birth rate (CLBR) within 1 year after treatment initiation in GnRH antagonist treatment cycles for in vitro fertilization (IVF).
Design
Observational (retrospective) substudy as part of an ongoing prospective cohort study.
Setting
University medical center.
Patient(s)
A total of 487 patients scheduled for IVF/intracytoplasmic sperm injection (ICSI).
Intervention(s)
Patients starting their first IVF/ICSI cycle with 150 or 225 IU recombinant FSH and GnRH antagonist cotreatment were included. Serum samples collected before the first IVF treatment were used to determine AMH. Treatment data after treatment initiation for a maximum of 1 year were recorded.
Main Outcome Measure(s)
Prediction of CLBR with the use of AMH.
Result(s)
The model for predicting CLBR within 1 year included age at first treatment, AMH, type of infertility, and previous assisted reproductive technology treatment leading to live birth. The accuracy in discriminating between women who did or did not achieve a live birth was only 59%. AMH had intermediate added value in the prediction of CLBR as demonstrated by the net reclassification improvement (total 29.8). A nomogram based on age and AMH was developed by which a subgroup of patients could be identified with the poorest pregnancy prospects.
Conclusion(s)
The predictive accuracy of AMH for 1-year CLBR in GnRH antagonist treatment cycles was limited and did not yield much additional value on top of age. Withholding treatment based on predictors such as age and AMH, or a combination, remains problematic.
Clinical Trial Registration Number
www.clinicaltrials.gov, NCT02309073.
IVF, AMH, live birth, GnRH antagonist
1-10
Hamdine, O.
5bb6c208-02f5-4210-a688-878ee41bafac
Eijkemans, M.
5d522c77-6054-4168-92a5-69909f866674
Lentjes, E.G.
f2a163a1-8a1d-4eaf-ad02-3618b5857f79
Torrance, H.L.
0f5cd815-11cb-47b6-b598-781e0a80ae3d
Macklon, N.S.
7db1f4fc-a9f6-431f-a1f2-297bb8c9fb7e
Broekmans, F.J.
17ce14de-42f9-43cb-98be-194dc9430888
18 July 2015
Hamdine, O.
5bb6c208-02f5-4210-a688-878ee41bafac
Eijkemans, M.
5d522c77-6054-4168-92a5-69909f866674
Lentjes, E.G.
f2a163a1-8a1d-4eaf-ad02-3618b5857f79
Torrance, H.L.
0f5cd815-11cb-47b6-b598-781e0a80ae3d
Macklon, N.S.
7db1f4fc-a9f6-431f-a1f2-297bb8c9fb7e
Broekmans, F.J.
17ce14de-42f9-43cb-98be-194dc9430888
Hamdine, O., Eijkemans, M., Lentjes, E.G., Torrance, H.L., Macklon, N.S. and Broekmans, F.J.
(2015)
Antimüllerian hormone: prediction of cumulative live birth in gonadotropin-releasing hormone antagonist treatment for in vitro fertilization.
Fertility and Sterility, .
(doi:10.1016/j.fertnstert.2015.06.030).
(PMID:26196233)
Abstract
Objective
To assess the accuracy of antimüllerian hormone (AMH) in predicting cumulative live birth rate (CLBR) within 1 year after treatment initiation in GnRH antagonist treatment cycles for in vitro fertilization (IVF).
Design
Observational (retrospective) substudy as part of an ongoing prospective cohort study.
Setting
University medical center.
Patient(s)
A total of 487 patients scheduled for IVF/intracytoplasmic sperm injection (ICSI).
Intervention(s)
Patients starting their first IVF/ICSI cycle with 150 or 225 IU recombinant FSH and GnRH antagonist cotreatment were included. Serum samples collected before the first IVF treatment were used to determine AMH. Treatment data after treatment initiation for a maximum of 1 year were recorded.
Main Outcome Measure(s)
Prediction of CLBR with the use of AMH.
Result(s)
The model for predicting CLBR within 1 year included age at first treatment, AMH, type of infertility, and previous assisted reproductive technology treatment leading to live birth. The accuracy in discriminating between women who did or did not achieve a live birth was only 59%. AMH had intermediate added value in the prediction of CLBR as demonstrated by the net reclassification improvement (total 29.8). A nomogram based on age and AMH was developed by which a subgroup of patients could be identified with the poorest pregnancy prospects.
Conclusion(s)
The predictive accuracy of AMH for 1-year CLBR in GnRH antagonist treatment cycles was limited and did not yield much additional value on top of age. Withholding treatment based on predictors such as age and AMH, or a combination, remains problematic.
Clinical Trial Registration Number
www.clinicaltrials.gov, NCT02309073.
This record has no associated files available for download.
More information
Accepted/In Press date: 25 June 2015
Published date: 18 July 2015
Keywords:
IVF, AMH, live birth, GnRH antagonist
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 379529
URI: http://eprints.soton.ac.uk/id/eprint/379529
ISSN: 0015-0282
PURE UUID: 37cd0187-d11a-42fe-8b57-5ae3c5787f56
Catalogue record
Date deposited: 04 Aug 2015 15:24
Last modified: 14 Mar 2024 20:42
Export record
Altmetrics
Contributors
Author:
O. Hamdine
Author:
M. Eijkemans
Author:
E.G. Lentjes
Author:
H.L. Torrance
Author:
N.S. Macklon
Author:
F.J. Broekmans
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics